BridgeBio Ranked No. 1 Small Employer by BioSpace for 2027
BridgeBio Pharma, Inc. has been named the top small employer in the life sciences industry for the second consecutive year in BioSpace's 2027 Best Places to Work list.
Stocks · News reference
BridgeBio Pharma Announces Upcoming Poster Presentations at AHA Scientific Sessions 2026
BridgeBio Pharma will present five posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM) at the American Heart Association Scientific Sessions 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Woven Health Collective Wins Healthcare Marketing Impact Award for BridgeBio VR Experience
A virtual reality experience developed for BridgeBio, titled 'From Clues to Clarity: Recognizing ATTR-CM,' received a Gold award at the 2026 Healthcare Marketing Impact Awards.
BridgeBio Pharma Announces Participation in Upcoming Healthcare Investor Conferences
BridgeBio Pharma management will participate in a series of fireside chats at four major healthcare investor conferences throughout November and December 2026.
BridgeBio Pharma Announces Equity Inducement Grants for New Employees
BridgeBio Pharma, Inc. reported the approval of equity grants in the form of restricted stock units for 80 new employees.
Canaccord Genuity Raises BridgeBio Pharma Price Target to $108
Canaccord Genuity has maintained its 'Buy' rating on BridgeBio Pharma while increasing the price target from $106 to $108.
Should You Invest $1,000 in BridgeBio Pharma Right Now?
BridgeBio Pharma is positioned for a potential breakout with three therapies approaching FDA approval over the next seven months. The company demonstrated strong commercial execution with Q3 2026 revenues up 193% year-over-year, driven primarily by its heart disease drug Attruby. With over $1.5 billion in cash and established sales teams ready for new product launches, BridgeBio appears well-positioned for growth, though risks remain inherent to small biotech companies focused on rare diseases.